AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01760343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL830
Description: CSL830 is a formulation of Berinert.
Study NCT01270815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 400 to 500 calories
Description: A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
Study NCT01270815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 600 to 750 calories
Description: A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
Study NCT01966367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD34 Stem Cell Selection Therapy
Description: The CliniMACS (PLUS) Reagent System (Miltenyi CliniMACS CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
Study NCT03237728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.06mg/kg,KB
Description: 0.06mg/kg,Q8h,Day1-Day7
Study NCT03237728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12mg/kg,KB
Description: 0.12mg/kg,Q8h,Day1-Day7
Study NCT03237728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.24mg/,KB
Description: 0.24mg/kg,Q8h,Day1-Day7
Study NCT03237728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: Placebos,Q8h,Day1-Day7
Study NCT02433236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium tablet 100 mg
Study NCT02433236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fostamatinib Disodium tablet 150 mg
Study NCT01270815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin controlled release, 330 mg, 800 to 1000 calories
Description: A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
Study NCT01270815 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin immediate release, 300 mg
Description: A single oral dose of 300 mg immediate release capsule administered fasted
Study NCT02465203 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Previous treatment in DEB025 study
Description: Follow-up after DEB025 active study
Study NCT00042991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: Given orally
Study NCT01832272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reinflation after early tourniquet deflation
Description: The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
Study NCT03125421 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: standard preventive methods of pressure sores
Description: During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.~The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage.
Study NCT03125421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: experimental multifaceted preventive methods of pressure sores
Description: During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.~The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected.
Study NCT02443727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Syntocinon (synthetic oxytocin)
Description: Dosage and details described in arm.
Study NCT02443727 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage and details described in arm.
Study NCT02314299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTP-131
Study NCT02206776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Ketamine
Description: A single dose of intranasal ketamine up to 50 mg
Study NCT02990429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forced Air warmer
Description: * record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using forced air warmer (bair hugger)~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop bair hugger~* record core temperature before recovery room
Study NCT02206776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Midazolam
Description: A single dose of intranasal Midazolam up to 4 mg
Study NCT02990429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intravenous Fluid Warmer
Description: * record room temperature~* record core temperature (tympanic membrane)~* General anesthesia~* using ranger warmer~* Intravenous fluid at room temperature~* room temperature and core temperature q15 minutes~* anesthesia finish, stop ranger warmer~* record core temperature before recovery room
Study NCT01356615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low molecular weight heparin (enoxaparin sodium)
Description: Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
Study NCT01356615 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard unfractionated heparin
Description: Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
Study NCT02061020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis (THC) in cigarettes of 30mg, 10mg and placebo
Description: Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.~Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.~Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).~Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours.
Study NCT04076930 — intervention group
Intervention type: DRUG
Intervention: angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB)
Description: The use of ACEI/ARB within a 90-day after the date of PD initiation (exposure ascertainment window period).
Study NCT05688917 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Green coffee been extract
Description: supportive treatment
Study NCT00042991 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo standard brain irradiation
Study NCT00042991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03841500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biocomposite intereference screw femoral tunnel fixation
Description: ACL reconstruction using biocomposite intereference screw for femoral tunnel fixation
Study NCT03841500 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobutton (Tightrope) femoral tunnel fixation
Description: ACL reconstruction using endobutton (Tightrope) for femoral tunnel fixation
Study NCT02094131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voldyne group (VG)
Description: VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions.
Study NCT05688917 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study NCT02287922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALX-0061
Study NCT02287922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02094131 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cliniflo group (CG)
Description: CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions.
Study NCT04647006 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: thyroid
Description: Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
Study NCT04647006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thyroid
Description: Conventional Thyroidectomy and Transoral endoscopic thyroidectomy vestibular approach
Study NCT04350749 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRF is added in the test group.
Description: The PRF membrane can be considered as a biological membrane
Study NCT04350749 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRF is added in the test group.
Description: The PRF membrane can be considered as a biological membrane
Study NCT00042991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01448499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine
Description: escalating dose of clozapine up to 900 mg/day
Study NCT01448499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amisulpride
Description: escalating dose of amisulpride up to 800 mg/day
Study NCT01448499 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clozapine+Amisulpride
Description: augmentation of clozapine with amisulpride
Study NCT04188145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine
Description: Option 1: Capecitabine 1250 mg/m2 twice daily (i.e. 2500 mg/m²/d) (D1 to D14, D1 = D22) For frail patients according to investigator evaluation capecitabine dose may be reduced to 1000 mg/m2 twice daily (2000 mg/m²/d).~Or Option 2: Capecitabine 625 mg/m2 twice daily (i.e. 1250 mg/m²/d) (D1 to D21, D1 = D22) Or Option 3: LV5FU2 simplified (folinic acid 200 mg/m² (or Elvorin 400 mg/m²) IV during 2h followed by 5-FU bolus IV of 400 mg/m² during 10 min and IV continuous 5-FU at 2400 mg/m² during 46h). (D1=D15).
Study NCT02287922 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Study NCT03182426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor
Description: Systemic CD34+ stem cell mobilization for beta-cell repair
Study NCT04188145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Option 1 and Option 2 : D1 bevacizumab 7.5 mg/kg IV (D1=D21). See smPCs for infusion time of bevacizumab.~Or Option 3: D1 bevacizumab 5 mg/kg IV (D1=D15). See smPCs for infusion time of bevacizumab
Study NCT00446173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: 130 mg/m\^2 IV Daily Over 3 Hours x 4 Days
Study NCT00446173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 60 mg/kg IV Daily Over 4 Hours x 2 Days
Study NCT00446173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 10 mcg/kg Subcutaneously Once Daily
Study NCT00446173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 250 mcg/kg Subcutaneously Once Daily
Study NCT03669289 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: enhanced model of primary care
Description: The SCHOOL STARS model of care includes pre-visit planning, standardized visit content, post-visit care coordination, and coordination between primary care and school.
Study NCT00639626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir [rDNA origin] injection
Description: Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
Study NCT03268291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard outpatient observation
Description: Outpatient management according to Ministry of health standards
Study NCT03268291 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communicational program Trust
Description: The developed program is based on the experience of international research studies and includes the following sections:~daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services.
Study NCT00367835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD503 (Guanfacine hydrochloride)
Description: Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
Study NCT00367835 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03850535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idasanutlin
Description: Participants will self-administer idasanutlin tablets by mouth (PO) once daily (QD) for 5 days of each 28-day treatment cycle for up to 2 cycles of induction, up to 4 cycles of consolidation, and 12 cycles of maintenance, according to the study's protocol.
Study NCT03182426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: T-cell depletion
Study NCT03182426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: Anti-inflammatory
Study NCT02079688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB011, 2 % (Water/Oil/Water) emulsion of hgd40
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Study NCT02079688 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple W/O/W formulation, active ingredient-free vehicle
Description: Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).~Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.~Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site
Study NCT03182426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Anti-inflammatory
Study NCT03182426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Beta-cell regeneration
Study NCT03850535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be administered for 7 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 200 milligrams per meter squared (mg/m\^2) of body surface area, once daily (QD) by intravenous (IV) infusion. At the investigator's discretion, cytarabine will also be administered as part of chemotherapy consolidation at a dose of 1.5 g/m\^2 QD as IV infusion for 5 days of each 28-day cycle and for up to 4 cycles of treatment.
Study NCT03850535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Daunorubicin will be administered for 3 days of each 28-day cycle for up to 2 cycles of induction treatment at a dose of 60 mg/m\^2 QD as IV infusion.
Study NCT03850535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Description: After induction treatment, participants who achieve remission will either receive chemotherapy consolidation treatment or undergo Allo-HSCT (as per local guidelines) at the investigator's discretion.
Study NCT02659436 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Verbal-linguistic CBT
Description: Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
Study NCT02659436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imagery-based CBT
Description: Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
Study NCT04481360 — intervention group
Intervention type: DEVICE
Intervention: CT of the chest
Description: Degree of affection on the lung infected by COVID19
Study NCT01590160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: IV, Using dose from Phase I
Study NCT02508428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Replacement with crosslinked Marathon polyethylene
Description: Comparison of Marathon and Enduron polyethylene
Study NCT02508428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hip Replacement with noncrosslinked Enduron polyethylene
Study NCT02078128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: oral beta-glucans
Description: 30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
Study NCT01740596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-Pulse® System Counterpulsation
Description: The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
Study NCT03051048 — intervention group
Intervention type: PROCEDURE
Intervention: Reperfusion
Study NCT01675882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 50 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
Study NCT01675882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Viaskin Peanut 100 mcg
Description: Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract